FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030824043> ?p ?o ?g. }

• W3030824043 endingPage "1978" @default.
• W3030824043 startingPage "1972" @default.
• W3030824043 abstract "Background The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. Methods The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performance status 0–1; age ≤ 75; adequate hematological, hepatic, and renal function. The patients were injected with 35 mg/m 2 amrubicin on days one, two, and three every 3–4 weeks. The planned number of patients was 32. Results The study was terminated due to delay in enrollment and 10 patients were subsequently enrolled (nine males and one female; median age 67 [range 49–73]), of which four had epithelioid tumors, three had sarcomatoid tumors and three had biphasic tumors, respectively. According to the International Mesothelioma Interest Group (IMIG), one, four, and four patients had stage II, III, and IV, respectively, and one had postoperative recurrence. There was one (10%) partial response, four (40%) had stable disease, and five (50%) patients exhibited disease progression. The overall response and disease control rates were 10% (95% CI: 0.3–44.5%) and 60% (95% CI: 26.2–87.8%), respectively. The median progression‐free survival time was 1.6 months. The median overall survival time was 6.6 months, and the one‐, two‐, and three‐year survival rates were 23%, 23%, and 0%, respectively. The observed grade 3 or 4 toxicities included neutropenia in six (60%) patients; leukopenia in five (50%) patients; and febrile neutropenia, thrombocytopenia, anemia, and pneumonia in one (10%) patient each. Conclusions There was not enough data to evaluate the efficacy because the study was terminated early. However, amrubicin showed limited activity and acceptable toxicities when used in previously treated malignant pleural mesothelioma patients." @default.
• W3030824043 created "2020-06-05" @default.
• W3030824043 creator A5011309423 @default.
• W3030824043 creator A5011453596 @default.
• W3030824043 creator A5021321317 @default.
• W3030824043 creator A5024606605 @default.
• W3030824043 creator A5027171470 @default.
• W3030824043 creator A5046810336 @default.
• W3030824043 creator A5050479290 @default.
• W3030824043 creator A5052317767 @default.
• W3030824043 creator A5071159100 @default.
• W3030824043 creator A5076225179 @default.
• W3030824043 creator A5077110924 @default.
• W3030824043 creator A5082056968 @default.
• W3030824043 creator A5082897973 @default.
• W3030824043 creator A5083827752 @default.
• W3030824043 creator A5086141560 @default.
• W3030824043 date "2020-05-28" @default.
• W3030824043 modified "2023-09-28" @default.
• W3030824043 title "Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase <scp>II</scp> study" @default.
• W3030824043 cites W1869777220 @default.
• W3030824043 cites W1976428603 @default.
• W3030824043 cites W1999102644 @default.
• W3030824043 cites W2034542762 @default.
• W3030824043 cites W2050014528 @default.
• W3030824043 cites W2051804117 @default.
• W3030824043 cites W2060818162 @default.
• W3030824043 cites W2094586578 @default.
• W3030824043 cites W2100576484 @default.
• W3030824043 cites W2102627969 @default.
• W3030824043 cites W2102689217 @default.
• W3030824043 cites W2115465348 @default.
• W3030824043 cites W2127235139 @default.
• W3030824043 cites W2134594118 @default.
• W3030824043 cites W2151439313 @default.
• W3030824043 cites W2163176419 @default.
• W3030824043 cites W2165750757 @default.
• W3030824043 cites W2167746331 @default.
• W3030824043 cites W2174424137 @default.
• W3030824043 cites W2215044613 @default.
• W3030824043 cites W2593193817 @default.
• W3030824043 cites W2808133785 @default.
• W3030824043 cites W2888754876 @default.
• W3030824043 cites W2909198142 @default.
• W3030824043 cites W2948619068 @default.
• W3030824043 cites W2960392213 @default.
• W3030824043 cites W2973933756 @default.
• W3030824043 cites W4245520901 @default.
• W3030824043 doi "https://doi.org/10.1111/1759-7714.13490" @default.
• W3030824043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7327919" @default.
• W3030824043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32462731" @default.
• W3030824043 hasPublicationYear "2020" @default.
• W3030824043 type Work @default.
• W3030824043 sameAs 3030824043 @default.
• W3030824043 citedByCount "4" @default.
• W3030824043 countsByYear W30308240432021 @default.
• W3030824043 countsByYear W30308240432022 @default.
• W3030824043 countsByYear W30308240432023 @default.
• W3030824043 crossrefType "journal-article" @default.
• W3030824043 hasAuthorship W3030824043A5011309423 @default.
• W3030824043 hasAuthorship W3030824043A5011453596 @default.
• W3030824043 hasAuthorship W3030824043A5021321317 @default.
• W3030824043 hasAuthorship W3030824043A5024606605 @default.
• W3030824043 hasAuthorship W3030824043A5027171470 @default.
• W3030824043 hasAuthorship W3030824043A5046810336 @default.
• W3030824043 hasAuthorship W3030824043A5050479290 @default.
• W3030824043 hasAuthorship W3030824043A5052317767 @default.
• W3030824043 hasAuthorship W3030824043A5071159100 @default.
• W3030824043 hasAuthorship W3030824043A5076225179 @default.
• W3030824043 hasAuthorship W3030824043A5077110924 @default.
• W3030824043 hasAuthorship W3030824043A5082056968 @default.
• W3030824043 hasAuthorship W3030824043A5082897973 @default.
• W3030824043 hasAuthorship W3030824043A5083827752 @default.
• W3030824043 hasAuthorship W3030824043A5086141560 @default.
• W3030824043 hasBestOaLocation W30308240431 @default.
• W3030824043 hasConcept C126322002 @default.
• W3030824043 hasConcept C141071460 @default.
• W3030824043 hasConcept C142724271 @default.
• W3030824043 hasConcept C2776178081 @default.
• W3030824043 hasConcept C2776517811 @default.
• W3030824043 hasConcept C2776694085 @default.
• W3030824043 hasConcept C2777063308 @default.
• W3030824043 hasConcept C2777407522 @default.
• W3030824043 hasConcept C2777714996 @default.
• W3030824043 hasConcept C2778248108 @default.
• W3030824043 hasConcept C2778850193 @default.
• W3030824043 hasConcept C2780873365 @default.
• W3030824043 hasConcept C71924100 @default.
• W3030824043 hasConcept C90924648 @default.
• W3030824043 hasConceptScore W3030824043C126322002 @default.
• W3030824043 hasConceptScore W3030824043C141071460 @default.
• W3030824043 hasConceptScore W3030824043C142724271 @default.
• W3030824043 hasConceptScore W3030824043C2776178081 @default.
• W3030824043 hasConceptScore W3030824043C2776517811 @default.
• W3030824043 hasConceptScore W3030824043C2776694085 @default.
• W3030824043 hasConceptScore W3030824043C2777063308 @default.
• W3030824043 hasConceptScore W3030824043C2777407522 @default.
• W3030824043 hasConceptScore W3030824043C2777714996 @default.

• next